Technology | August 11, 2009

Pathway Medical Technologies Introduces Jetstream G2 NXT Atherectomy Catheter


August 11, 2009 – Pathway Medical Technologies Inc. today introduced the 7 French compatible version of its peripheral atherectomy catheter, the Jetstream G2 NXT.

The catheter is based on the company’s catheter technology capable of treating the entire spectrum of disease found in patients suffering from peripheral artery disease (PAD), including hard and soft plaque, calcium, fibrotic lesions and thrombus. The 7 Fr. compatibility allows physicians to use Jetstream G2 NXT in the treatment of PAD in a more diverse patient population, significantly expanding the number of patients who can now benefit from this innovative technology, the company said.

“The 7 Fr. compatible Jetstream G2 NXT is nearly identical to Jetstream G2, but has the advantages associated with smaller sheath technology,” said Dr. Robert Bersin at Seattle Cardiology. “As such, it expands my ability to treat more anatomies and patients with varying degrees of PAD.”

Jetstream G2 NXT is a peripheral atherectomy catheter designed to remove all kinds of artery-clogging plaque in the lower limbs of patients. This innovative and minimally invasive solution clears blockages in the peripheral vasculature, restores blood flow and effectively treats PAD.

Jetstream G2 NXT consists of a sterile, single-use catheter and control pod and a reusable, compact console that mounts to a standard I.V. stand. The catheter has an expandable cutting tip that safely debulks and preemptively removes both hard and soft plaque, as well as calcium, thrombus and fibrotic lesions. A highly efficient aspiration port located just proximal to the cutting blades continually removes excised tissue and thrombus from the treatment site to a collection bag located on the console. The distal portion of the catheter also possesses infusion ports that provide continuous infusion of sterile saline during the atherectomy procedure. Active aspiration is a safety feature that minimizes the risk of distal embolization.

For more information: www.pathwaymedical.com


Related Content

News | Atherectomy Devices

February 15, 2023 — Abbott and Cardiovascular Systems, Inc. (CSI), announced a definitive agreement for Abbott to ...

Home February 15, 2023
Home
News | Atherectomy Devices

July 28, 2022 — Northeast Scientific Inc., pioneers in reprocessing single use peripheral vascular catheters, announced ...

Home July 28, 2022
Home
News | Atherectomy Devices

March 9, 2022 — Medtronic is recalling (correcting) the TurboHawk Plus Directional Atherectomy System due to design ...

Home March 09, 2022
Home
News | Atherectomy Devices

January, 24, 2022 — Medtronic Inc. is recalling its HawkOne Directional Atherectomy System product due to the risk of ...

Home January 24, 2022
Home
News | Atherectomy Devices

January 10, 2022 — Cardiovascular Systems Inc. (CSI) is recalling the Wirion atherectomy embolic protection device ...

Home January 10, 2022
Home
News | Atherectomy Devices

July 20, 2020 – BD (Becton, Dickinson and Company) recently completed the acquisition of Straub Medical AG, a privately ...

Home July 20, 2020
Home
News | Atherectomy Devices

February 13, 2020 — The U.S. Food and Drug Administration (FDA) has issued its final guidance on "Peripheral Vascular ...

Home February 13, 2020
Home
News | Atherectomy Devices

November 7, 2019 — The REVEAL FDA investigational device exemption (IDE) trial confirmed a favorable safety and ...

Home November 11, 2019
Home
News | Atherectomy Devices

November 7, 2019 — There was no difference between drug-coated balloons (DCB) vs. plain old balloon angioplasty (POBA) ...

Home November 07, 2019
Home
Technology | Atherectomy Devices

September 13, 2019 — Rex Medical L.P. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for ...

Home September 13, 2019
Home
Subscribe Now